Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Thyroid Neoplasms × Vemurafenib × Clear all

Phase

Phase 2 2 Phase 1 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Heterotaxy Syndrome 1 Breast Neoplasms 1

Interventions

durvalumab 1 Vemurafenib 1 Thyrotropin Alfa 1 Probiotics 1 Iodine-131 1 Bexarotene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02145143 2025-06-18

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed

Thyroid Neoplasms, Heterotaxy Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡